{"id":"aee95dc3-ff09-5ac0-a42a-cd19f2b38b0f","stable_key":"fd37d270-3395-56d6-9f1c-ddda56e606f6:arg-mi-deaths","predicate":"associated_with_higher_trial_mortality","statement":"Six arginine-group participants died versus none receiving placebo; enrollment stopped for safety concerns.","claim_class":"observational","status":"source_derived_draft","evidence_grade":"ungraded","direction":"positive","is_public":true,"mechanism_event_id":"b5a4efbd-33e2-5d44-961f-cd9ae264164d","mechanism_event_label":"The clinical harm signal is retained alongside the mechanism records.","subject":{"id":"eeca3c9e-7749-5677-b7bd-37fe8f7c228d","slug":"arginine","display_name":"L-Arginine","entity_type_key":"small_molecule"},"object":{"id":"396becd5-6426-5a42-a3ae-36b30b9a08c7","slug":"post-mi-mortality","display_name":"Mortality in the post-MI arginine trial","entity_type_key":"cellular_process"},"evidence_count":1,"mechanism_event":{"id":"b5a4efbd-33e2-5d44-961f-cd9ae264164d","stable_key":"fd37d270-3395-56d6-9f1c-ddda56e606f6:arg-mi-deaths-event","event_type":"observed_relationship","label":"The clinical harm signal is retained alongside the mechanism records.","description":"Six arginine-group participants died versus none receiving placebo; enrollment stopped for safety concerns.","status":"provisional","compartment":null,"participants":[{"entity":{"id":"eeca3c9e-7749-5677-b7bd-37fe8f7c228d","slug":"arginine","display_name":"L-Arginine","entity_type_key":"small_molecule"},"role":"subject","stoichiometry":null,"state_label":"","sequence_order":0,"notes":""},{"entity":{"id":"396becd5-6426-5a42-a3ae-36b30b9a08c7","slug":"post-mi-mortality","display_name":"Mortality in the post-MI arginine trial","entity_type_key":"cellular_process"},"role":"target","stoichiometry":null,"state_label":"","sequence_order":1,"notes":""}]},"contexts":[{"dimension":"evidence_access","value_text":"Primary abstract","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"experimental_model","value_text":"VINTAGE MI randomized post-infarction trial.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"limitations","value_text":"Small event count; causal molecular explanation unresolved. The trial authors advised against use following acute MI.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"nutrient_topic","value_text":"L-Arginine collection; tissue, species, dose and formulation distinctions retained.","comparator":null,"unit":null,"notes":"","entity":{"slug":"arginine","display_name":"L-Arginine","entity_type_key":"small_molecule"}},{"dimension":"plain_language","value_text":"The clinical harm signal is retained alongside the mechanism records.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"primary_references","value_text":"L-arginine therapy in acute myocardial infarction: the Vascular Interaction With Age in Myocardial Infarction (VINTAGE MI) randomized clinical trial. · 2006 · https://pubmed.ncbi.nlm.nih.gov/16391217/ · DOI 10.1001/jama.295.1.58","comparator":null,"unit":null,"notes":"","entity":null}],"evidence":[{"id":"2af1efe1-3229-5fd5-a4d3-00d8bcd6e122","evidence_kind":"source_excerpt","locator":"Lines 382-388","start_line":382,"end_line":388,"excerpt":"## arg-mi-deaths\nThe clinical harm signal is retained alongside the mechanism records.\nSix arginine-group participants died versus none receiving placebo; enrollment stopped for safety concerns.\nModel: VINTAGE MI randomized post-infarction trial.\nLimitations: Small event count; causal molecular explanation unresolved. The trial authors advised against use following acute MI.\nEvidence access: Primary abstract\nL-arginine therapy in acute myocardial infarction: the Vascular Interaction With Age in Myocardial Infarction (VINTAGE MI) randomized clinical trial. · 2006 · https://pubmed.ncbi.nlm.nih.gov/16391217/ · DOI 10.1001/jama.295.1.58","model_system":"VINTAGE MI randomized post-infarction trial.","directness":"reported_statement","verification_status":"source_derived_draft","notes":"Original curation paraphrase; primary evidence access stated per claim.","relationship":"supports","weight":1.0,"link_notes":"","source":{"id":"bb9a67ea-904f-5b8a-93a4-459081212bdd","stable_key":"import-fd37d270-3395-56d6-9f1c-ddda56e606f6","title":"L-Arginine: transport, metabolic branches, nutrient interactions, availability and discovery questions (2026-09-18)","document_type":"imported_text","citation_label":"AI-assisted research curation; primary-abstract references and experimental limitations individually identified. Not publisher full text.","file_path":"","sha256":"ec0e9a3fb72b7485534e4372a074ac7624a399ff962e55690eb462217b5149ec","revision_id":"af027270-5535-51ae-85ff-9c76c518c962","review_status":"unverified_draft","notes":""}}],"relations":[],"conflicts":[],"corrections":[],"research":null}